Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

S Amele; L Peters; M Sluzhynska; A Yakovlev; A Scherrer; P Domingo; J Gerstoft; J P Viard; M Gisinger; R Flisiak; S Bhaghani; M Ristola; C Leen; E Jablonowska; G Wandeler; H Stellbrink; K Falconer; A D'Arminio Monforte; A Horban; J K Rockstroh; J D Lundgren; A Mocroft; EuroSIDA study group

doi:10.1111/hiv.12711

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

S Amele, L Peters, M Sluzhynska, A Yakovlev, A Scherrer, P Domingo, J Gerstoft, J P Viard, M Gisinger, R Flisiak, S Bhaghani, M Ristola, C Leen, E Jablonowska, G Wandeler, H Stellbrink, K Falconer, A D'Arminio Monforte, A Horban, J K RockstrohJ D Lundgren, A Mocroft, EuroSIDA study group

Afdeling for Infektionssygdomme HJE

9 Citationer (Scopus)

Abstract

OBJECTIVES: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy.

METHODS: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment.

RESULTS: Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001).

CONCLUSIONS: In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

Originalsprog	Engelsk
Tidsskrift	HIV Medicine
Vol/bind	20
Udgave nummer	4
Sider (fra-til)	264-273
Antal sider	10
ISSN	1464-2662
DOI	https://doi.org/10.1111/hiv.12711
Status	Udgivet - 1 apr. 2019

Adgang til dokumentet

10.1111/hiv.12711

Citationsformater

Amele, S., Peters, L., Sluzhynska, M., Yakovlev, A., Scherrer, A., Domingo, P., Gerstoft, J., Viard, J. P., Gisinger, M., Flisiak, R., Bhaghani, S., Ristola, M., Leen, C., Jablonowska, E., Wandeler, G., Stellbrink, H., Falconer, K., D'Arminio Monforte, A., Horban, A., ... EuroSIDA study group (2019). Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Medicine, 20(4), 264-273. https://doi.org/10.1111/hiv.12711

Amele, S, Peters, L, Sluzhynska, M, Yakovlev, A, Scherrer, A, Domingo, P, Gerstoft, J, Viard, JP, Gisinger, M, Flisiak, R, Bhaghani, S, Ristola, M, Leen, C, Jablonowska, E, Wandeler, G, Stellbrink, H, Falconer, K, D'Arminio Monforte, A, Horban, A, Rockstroh, JK, Lundgren, JD, Mocroft, A & EuroSIDA study group 2019, 'Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA', HIV Medicine, bind 20, nr. 4, s. 264-273. https://doi.org/10.1111/hiv.12711

@article{368cedca698c4646bb38149587d06431,

title = "Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA",

abstract = "OBJECTIVES: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy.METHODS: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment.RESULTS: Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001).CONCLUSIONS: In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.",

keywords = "continuum of care, Europe, HIV/HCV coinfection, sustained virological response, treatment",

author = "S Amele and L Peters and M Sluzhynska and A Yakovlev and A Scherrer and P Domingo and J Gerstoft and Viard, {J P} and M Gisinger and R Flisiak and S Bhaghani and M Ristola and C Leen and E Jablonowska and G Wandeler and H Stellbrink and K Falconer and {D'Arminio Monforte}, A and A Horban and Rockstroh, {J K} and Lundgren, {J D} and A Mocroft and {EuroSIDA study group}",

note = "{\textcopyright} 2019 British HIV Association.",

year = "2019",

month = apr,

day = "1",

doi = "10.1111/hiv.12711",

language = "English",

volume = "20",

pages = "264--273",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

AU - Amele, S

AU - Peters, L

AU - Sluzhynska, M

AU - Yakovlev, A

AU - Scherrer, A

AU - Domingo, P

AU - Gerstoft, J

AU - Viard, J P

AU - Gisinger, M

AU - Flisiak, R

AU - Bhaghani, S

AU - Ristola, M

AU - Leen, C

AU - Jablonowska, E

AU - Wandeler, G

AU - Stellbrink, H

AU - Falconer, K

AU - D'Arminio Monforte, A

AU - Horban, A

AU - Rockstroh, J K

AU - Lundgren, J D

AU - Mocroft, A

AU - EuroSIDA study group

PY - 2019/4/1

Y1 - 2019/4/1

N2 - OBJECTIVES: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy.METHODS: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment.RESULTS: Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001).CONCLUSIONS: In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

AB - OBJECTIVES: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy.METHODS: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment.RESULTS: Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001).CONCLUSIONS: In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

KW - continuum of care

KW - Europe

KW - HIV/HCV coinfection

KW - sustained virological response

KW - treatment

U2 - 10.1111/hiv.12711

DO - 10.1111/hiv.12711

M3 - Journal article

C2 - 30734998

SN - 1464-2662

VL - 20

SP - 264

EP - 273

JO - HIV Medicine

JF - HIV Medicine

IS - 4

ER -

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater